We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
REGENXBIO Inc | NASDAQ:RGNX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.19 | 1.14% | 16.83 | 14.00 | 23.59 | 17.52 | 16.68 | 17.24 | 239,865 | 05:00:06 |
Chardan Inaugural Gene Therapy ConferenceDate: Tuesday, October 10, 2017Location: The Westin New York Grand Central HotelFireside chat: Tuesday, October 10, 2017 at 9:30 a.m. ETPanel: Gene Therapies: Pricing and Other Commercial Considerations; Tuesday, October 10, 2017 at 4:15 p.m. ET
Jefferies Gene Therapy Technology Investor SummitDate: Thursday, October 12, 2017Location: The Westin New York Grand Central HotelFireside chat: Thursday, October 12, 2017 at 3:10 p.m. ET
A live webcast of each presentation can be accessed in the Investors section of REGENXBIO’s website at www.regenxbio.com. An archived replay of each webcast will be available on the same website for approximately 30 days following the presentation. In addition, REGENXBIO senior management will be holding one-on-one meetings at each of the conferences.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
CONTACT:
Investors Natalie Wildenradt, 646-681-8192 natalie@argotpartners.com
Media Adam Pawluk, 202-591-4063 apawluk@jpa.com
1 Year REGENXBIO Chart |
1 Month REGENXBIO Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions